Aug. 11 at 12:28 PM
$CNTB Connect quietly registered another Phase 2 rademikibart study. NCT07705737, a 40-patient, open-label Phase 2 trial testing a single 300 mg IV dose of rademikibart in patients arriving for urgent treatment of an acute asthma or COPD exacerbation. The primary endpoint is change in FEV1 at one week; the study was registered in July and lists completion around December 2026.
CNTB already knows the blinded Seabreeze results only to the extent permitted before database lock/unblinding - but this is still bullish imo.
They are spending money and operational bandwidth before the Seabreeze readouts to expand the exact acute-exacerbation concept they’re betting the company on. And they’re specifically testing the IV formulation that previously produced very rapid lung-function improvement.
